By Nadine Sprangers (Daiichi Sankyo)2024-08-30T10:00:16
Nadine Sprangers is Vice President, Head of Global Oncology Value, Access and Pricing at Daiichi Sankyo. Holding a PharmD degree and two Master’s Degrees, she leads a team of 50 people responsible for setting the global strategic framework for Pricing, Reimbursement, and Access (PRA), Health Economics and Outcome Research (HEOR), ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-15T13:47:00Z
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2023-07-04T10:05:58
Sponsored by Revvity
2026-05-05T13:24:00
Sponsored by HUB Organoids
2024-01-26T13:22:42
Sponsored by bit.bio
2024-03-08T10:00:25
Sponsored by Molecular Devices
Site powered by Webvision Cloud